Phagelux Raises Capital from Fosun Pharma

Phagelux, a Shanghai company developing bacteriophages as an alternative to antibiotics, raised an undisclosed amount of capital from Fosun Pharma.  Mark Engel, CEO of Phagelux, called the transaction a "milestone" and Fosun a "strategic partner." Phagelux operates labs in Nanjing and Montreal. It opened a pilot production facility in Suzhou last month, and it plans to open a dedicated lysin development facility in Wuhan this month. More details.... Stock Symbol: (SH: 600196, HK: 02196) Share this with colleagues: // //